Evaluation of the effect of Olopatadine nasal spray compared to Mometasone spray in the treatment of allergic rhinosinusitis cases refered to ENT clinic of Heshmatieh Hospital Sabzevar

Evaluation of the effect of olapatadine nasal spray in comparison with mometasone spray in the treatment of allergic rhinosinusitis

A clinical trial study with two intervention groups, with parallel groups, double-blind, randomized, is performed on 100 patients. Balanced Block Randomization method is used for randomization.

This is an interventional study that will be performed on patients with allergic rhinosinusitis referred to the ENT clinic of Heshmatieh Hospital in Sabzevar from September 1, 2016. Patients are randomly assigned to the study groups based on the Balanced Block Randomization method. Symptoms of allergic rhinosinusitis in patients before the intervention are scored according to the SNOT22 questionnaire. Then, on the first, third and fourteenth day after starting treatment, patients will answer the SNOT22 questionnaire again.

Conditions of entry: age 18 to 60 years; Patients with confirmed allergic rhinosinusitis; Written consent to enter the study; Patient cooperation during the study; Timely and correct use of medication; Absence of abnormal nasal anatomy; Absence of severe nasal congestion due to polyps, other lesions and obstructive masses; Absence of respiratory infections; Non-smokers; Absence of upper and lower lung diseases affecting the final consumption or absorption of the nose; Absence of symptoms of systemic diseases Conditions of non-entry: individuals known for not responding to antihistamines; Known intolerance or sensitivity to drugs

Intervention group 1: administration of Olopatadine nasal spray 0.6% every 12 hours (made by Daroo Pakhsh Tehran) Intervention group 2: administration of Mometasone 50 mg nasal spray every 6 hours (made by Caspian Drug Company of Rasht)

Response to treatment in the studied groups, patient satisfaction

For randomization, a simple block method will be used. The individual randomization unit and the randomization tool are sealed drug packages that are completely similar in shape and the patient and the project operator are not aware of the contents of the packages. The allocation of samples in the study will be based on a random sequence provided by the statistical consultant using statistical software. The sequence used will be quadruple blocks. Random allocation software is also a tool for generating random block sequences.

In order to blind each patient, it is numbered by the supervisor and recorded in a notebook; For example, patient No. 1 receives box A medicine and patient number 2 receives box B medicine. While the researcher and patients do not know the content of the drug in the envelopes.